현대ADM
Financials
Valuation Metrics
현대ADM's Market Cap is ₩4318B. At end of 2025 it was ₩1478B. Ranked #543 of 2,419 in KR market (top 22%), #222 of 1,638 on KOSDAQ (top 14%), #59 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 431.77B KRW | KR#543/2,419 Sec#59/231 |
| Revenue | 8.34B KRW | KR#2,303/2,419 Sec#182/231 |
| Net Income | -16.36B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 34.14B KRW | KR#2,310/2,419 Sec#214/231 |
| Net Assets | 22.94B KRW | KR#2,255/2,419 Sec#210/231 |
| Employees | 159 | KR#1,273/2,419 Sec#104/231 |
| Value | ||
| P/B | 18.82x | KR#2,397/2,419 Sec#222/231 |
| P/S | 51.74x | KR#2,372/2,419 Sec#198/231 |
| FCF Yield | -1.21% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -71.34% | KR#2,323/2,419 Sec#211/231 |
| ROA | -47.94% | KR#2,360/2,419 Sec#215/231 |
| Op. Margin | -80.30% | KR#2,286/2,419 Sec#169/231 |
| Revenue Growth | -6.48% | KR#1,830/2,419 Sec#173/231 |
| Earnings Growth | -274.47% | KR#1,264/2,419 Sec#88/231 |
| Financial Health | ||
| Debt Ratio | 48.83% | KR#945/2,419 Sec#108/231 |
| Total Debt | 5.00B KRW | KR#1,784/2,419 Sec#170/231 |
| FCF | -5.22B KRW | KR#1,505/2,419 Sec#118/231 |
| Cash | 424.3M KRW | KR#2,368/2,419 Sec#225/231 |
| Current Ratio | 0.49x | KR#2,150/2,419 Sec#208/231 |
| Performance | ||
| 1Y Return | 174.73% | KR#81/2,419 Sec#3/231 |
| 1M Return | 4.33% | KR#824/2,419 Sec#84/231 |
| From 52W High | -67.68% | KR#2,160/2,419 Sec#190/231 |
| 1Y MDD | -81.53% | KR#2,318/2,419 Sec#215/231 |
| Trading | ||
| Volume | 518,025 shares | KR#238/2,419 Sec#33/231 |
| Trading Value | 3.54B KRW | KR#445/2,419 Sec#57/231 |
| Foreign Own. | 1.17% | KR#1,957/2,419 Sec#192/231 |
| Per Share | ||
| EPS | -256 KRW | KR—/2,419 Sec—/231 |
| BPS | 359 KRW | KR#2,400/2,419 Sec#228/231 |
Company Info
Established in 2003, this Contract Research Organization (CRO) was acquired by Hyundai Bioscience in 2024. It holds exclusive rights to drug delivery technology and provides comprehensive services to pharmaceutical companies and bio-ventures, including clinical trial design, monitoring, and data management. The company is developing breast and lung cancer treatments using inorganic material-based drug delivery system technology. It aims to become a global specialized oncology company through digital clinical trials leveraging AI, Big Data, and remote monitoring. Hyundai ADM is headquartered in Jongno-gu, Seoul.